MDGH Invests in PCI Pharma Services
Why we think this is neutral
The RNS announcement does not contain any of the mandatory news types, such as contract news, order news, trading update, financing, funding, annual results, asset sale/disposal, flow testing, licence news, or delisting. Therefore, the sentiment is neutral.
Key Points
- MDGH subsidiary to reinvest into PCI Pharma Services
- PCI Pharma Services is a global contract development and manufacturing organization
- Transaction subject to closing conditions and regulatory approvals
Summary
The company has announced an investment into PCI Pharma Services, a contract development and manufacturing organization.
MDGH, a diversified global holding company, has announced that a wholly-owned subsidiary has entered into an agreement to reinvest into PCI Pharma Services, a global contract development and manufacturing organization focused on innovative biotherapies. The completion of the transaction is subject to customary closing conditions and regulatory approvals.
GENERAL UPDATE